In vivo Modulation of the Immune System by Mafosfamide in Patients with Advanced Renal Cell Carcinoma. A Phase I Trial

1989 ◽  
pp. 255-258
Author(s):  
H. O. Klein ◽  
C. Coerper ◽  
P. Voigt ◽  
G. Golbach
Keyword(s):  
Renal Cell Carcinoma ◽  
Immune System ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Advanced Renal Cell Carcinoma

NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma

2020 ◽  
Vol 38 (5) ◽  
pp. 1383-1389
Author(s):  
Ana M. Molina ◽  
Johannes C. van der Mijn ◽  
Paul Christos ◽  
John Wright ◽  
Charlene Thomas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Advanced Renal Cell Carcinoma

In Vivo and In Vitro Effects of Xenogeneic Immune Ribonucleic Acid in Patients With Advanced Renal Cell Carcinoma: A Phase I Study

1981 ◽  
Vol 126 (1) ◽  
pp. 24-27 ◽  
Author(s):  
Jerome P. Richie ◽  
Bosco S. Wang ◽  
Glenn D. Steele ◽  
Richard E. Wilson ◽  
John A. Mannick
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Ribonucleic Acid ◽  
Renal Cell ◽  
Phase I Study ◽  
Advanced Renal Cell Carcinoma ◽  
In Vitro Effects

A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma

2011 ◽  
Vol 34 (5) ◽  
pp. 443-448 ◽  
Author(s):  
Scott T. Tagawa ◽  
Matthew I. Milowsky ◽  
Stephanie Jeske ◽  
Madhu Mazumdar ◽  
Sophia Kung ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Advanced Renal Cell Carcinoma

Phase I trial of interferon ?2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma

Cancer ◽  
2002 ◽  
Vol 95 (6) ◽  
pp. 1220-1227 ◽  
Author(s):  
Jonathan S. Goldberg ◽  
Manuel Vargas ◽  
Alyssa S. Rosmarin ◽  
Matthew I. Milowsky ◽  
Nicholas Papanicoloau ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Advanced Renal Cell Carcinoma ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

scholarly journals Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma

2006 ◽  
Vol 12 (15) ◽  
pp. 4619-4627 ◽  
Author(s):  
Jared A. Gollob ◽  
Catherine J. Sciambi ◽  
Bercedis L. Peterson ◽  
Tina Richmond ◽  
Monica Thoreson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Low Dose ◽  
Interleukin 2 ◽  
High Dose ◽  
Intravenous Bolus

scholarly journals A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinoma

1995 ◽  
Vol 6 (9) ◽  
pp. 911-914 ◽  
Author(s):  
R. Amato ◽  
C. Meyers ◽  
J. Ellerhorst ◽  
L. Finn ◽  
R. Kilbourn ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
High Dose

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

2001 ◽  
Vol 19 (5) ◽  
pp. 1312-1319 ◽  
Author(s):  
Robert J. Motzer ◽  
Ashok Rakhit ◽  
Michelle Ginsberg ◽  
Karen Rittweger ◽  
Jacqueline Vuky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Serum Concentration ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Subcutaneous Administration ◽  
Interferon Alfa ◽  
Advanced Renal Cell Carcinoma ◽  
Grade 3 ◽  
Dose Limiting Toxicity

PURPOSE: Pegylated (40 kd) interferon alfa-2a (IFNα2a) (PEGASYS, Hoffman-La Roche, Nutley, NJ; PEG-IFN) is a modified form of recombinant human IFNα2a with sustained absorption and prolonged half-life after subcutaneous administration. A phase I study of PEG-IFN with pharmacokinetic and pharmacodynamic evaluations was conducted in previously untreated patients with advanced renal cell carcinoma (RCC). PATIENTS AND METHODS: Twenty-seven patients were enrolled onto cohorts of three or six patients. PEG-IFN was administered on a weekly basis by subcutaneous injection. The dose was escalated from 180 μg/wk to a maximum of 540 μg/wk in 90-μg increments. Serial venous blood samples were drawn to assess concentrations of PEG-IFN and two immunologic surrogates, neopterin and 2′-5′ oligoadenylate synthetase (OAS). RESULTS: The maximum-tolerated dose was determined as 540 μg/wk, because two patients experienced dose-limiting toxicity within 28 days of starting treatment. One developed serum grade 3 ALT elevation, and a second developed grade 3 fatigue. Six patients were treated at 450 μg/wk without dose-limiting toxicity. Over the course of treatment, the side-effect profile was mostly mild to moderate in intensity. Adverse events included fatigue, fever, headache, myalgia, nausea, and decreased appetite. Five patients (19%) achieved a partial response. The mean maximum serum concentration increased from 5.0 to 27 ng/mL, and mean area under the curve increased from 247 to 2,981 ng/h/mL, with dose escalation from 180 μg/wk to 540 μg/wk. Serum concentration of PEG-IFN was sustained at close to peak during the dosing interval, and steady-state was achieved in approximately 5 weeks. The immunologic surrogates, neopterin and OAS, were induced at all doses with a sustained concentration profile similar to PEG-IFN. CONCLUSION: PEG-IFN is a modified form of IFNα2a with distinct pharmacokinetic advantages and immunomodulatory and antitumor activity for patients with advanced RCC. A dose of 450 μg/wk by subcutaneous administration was determined as a suitable dose for further study. PEG-IFN is more convenient to administer than IFNα and has potential for increased efficacy, less toxicity, or both. The efficacy and toxicity of PEG-IFN will be further assessed in clinical trials and compared with IFNα.

scholarly journals PV-0550: Combined high dose radiation and tyrosine kinase inhibitors in renal cell carcinoma: a phase I trial

2017 ◽  
Vol 123 ◽  
pp. S293-S294
Author(s):  
K. De Wolf ◽  
S. Rottey ◽  
K. Vermaelen ◽  
K. Decaestecker ◽  
N. Sundahl ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Phase I ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell ◽  
Phase I Trial ◽  
Kinase Inhibitors ◽  
High Dose ◽  
Dose Radiation
Sign in / Sign up

Export Citation Format

Share Document